Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6‐hydroxydopamine
- 1 March 1998
- journal article
- research article
- Published by Wiley in Movement Disorders
- Vol. 13 (2) , 242-248
- https://doi.org/10.1002/mds.870130208
Abstract
A significant body of evidence has been provided to support the hypothesis that oxidant stress may be responsible for the degeneration of dopaminergic neurons in the substantia nigra pars compacta in Parkinson's disease. Apomorphine, a dopamine D1/D2‐receptor agonist in the clinical therapy of Parkinson's disease, has been found to be a potent antioxidant and to prevent free radical reaction in rat brain mitochondrial fraction. In this article we show that 1–10 μM of apomorphine protects rat pheochromocytoma (PC12) cells from the toxic effects of H2O2 (0.6 mM) and the neurotoxin 6‐hydroxydopamine (150 μM). These effects were not exhibited by ascorbic acid, desferal, lisuride, or bromocriptine. Although pergolide exhibited some protection of PC12 cells against H2O2 toxicity, it was not as potent as apomorphine. In light of the present findings and the clinical reports that parkinsonian patients on long‐term apomorphine stabilize clinically and can be weaned off L‐dopa, one may assume that apomorphine can exert a neuroprotective activity via its potent antioxidant properties.Keywords
This publication has 26 references indexed in Scilit:
- Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.Journal of Neurology, Neurosurgery & Psychiatry, 1996
- Peroxynitrite‐Induced Cytotoxicity in PC12 Cells: Evidence for an Apoptotic Mechanism Differentially Modulated by Neurotrophic FactorsJournal of Neurochemistry, 1995
- The Therapeutic Potential of Moclobemide, a Reversible Selective Monoamine Oxidase A Inhibitor in Parkinson's DiseaseJournal of Clinical Psychopharmacology, 1995
- Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease.Journal of Clinical Investigation, 1995
- The inherent cytotoxicity of melanin precursors: A revisionBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1994
- The determination of hydroxydopamines and other trace amines in the urine of Parkinsonian patients and normal controlsNeurochemical Research, 1993
- Dopamine agonists in Parkinson's disease: a look at apomorphineFundamental & Clinical Pharmacology, 1993
- The Iron Chelator Desferrioxamine (Desferal) Retards 6‐Hydroxydopamine‐Induced Degeneration of Nigrostriatal Dopamine NeuronsJournal of Neurochemistry, 1991
- Iron in Brain Function and Dysfunction with Emphasis on Parkinson’s DiseaseEuropean Neurology, 1991